Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial
Are there any red flags or uncertainties in the update (e.g., patient enrollment rates, trial delays) that could pose downside risk?
What is the expected impact on the company's revenue forecast for 2025‑2026 given the projected clinical and IP milestones?
How might the trial results, if positive or negative, shift analyst consensus and target price estimates?
9 days ago